|
Market Closed -
Other stock markets
|
5-day change | 1st Jan Change | ||
| 0.752 EUR | -1.44% |
|
-9.40% | -90.76% |
| Apr. 24 | Transcript : Vivoryon Therapeutics N.V., 2023 Earnings Call, Apr 24, 2024 | |
| Mar. 15 | Vivoryon Therapeutics N.V Announces Resignation of Board of Directors | CI |
Probiodrug AG announced that Mark Booth has joined the company as Chief Business Officer and member of the Management Board. Mark Booth most recently served as the Chief Commercial Officer at Orexigen Therapeutics Inc.
| 1st Jan change | Capi. | |
|---|---|---|
| -90.76% | 21.62M | |
| +33.37% | 49.46B | |
| +1.55% | 42.58B | |
| +49.11% | 42.49B | |
| -4.22% | 29.09B | |
| +11.57% | 26.61B | |
| -21.00% | 18.64B | |
| +7.36% | 13.16B | |
| +28.30% | 12.55B | |
| +23.80% | 12.1B |
VIVORYON THERAPEUTICS N.V. 